Categoría: Articulos
-
Why is family disclosure of genetic risk so difficult? A collaborative analysis of 685 rare-disease patient experiences
European Journal of Human Genetics, Published online: 21 August 2026; doi:10.1038/s41431-026-02205-8Why is family disclosure of genetic risk so difficult? A collaborative analysis of 685 rare-disease patient experiences
-
Why is family disclosure of genetic risk so difficult? A collaborative analysis of 685 rare-disease patient experiences
European Journal of Human Genetics, Published online: 21 August 2026; doi:10.1038/s41431-026-02205-8Why is family disclosure of genetic risk so difficult? A collaborative analysis of 685 rare-disease patient experiences
-
A unified framework to explain one of cancer’s major drivers
In a rare pair of papers published back-to-back in the journal Genes & Development, research teams led by senior author Anindya Bagchi, Ph.D., associate professor in the Cancer Genome and Epigenetics Program at Sanford Burnham Prebys Medical Discovery …
-
A unified framework to explain one of cancer’s major drivers
In a rare pair of papers published back-to-back in the journal Genes & Development, research teams led by senior author Anindya Bagchi, Ph.D., associate professor in the Cancer Genome and Epigenetics Program at Sanford Burnham Prebys Medical Discovery …
-
Highly Accurate Detection of Circulating Tumor DNA for Monitoring Minimal Residual Disease in Solid Tumors: Analytical and Clinical Validation of the Haystack MRD Assay
Advances in cell-free DNA (cfDNA) processing and error-suppressed next-generation sequencing (NGS) have enabled detection of circulating tumor DNA (ctDNA) at low abundance for assessment of minimal residual disease (MRD). MRD testing requires high anal…
-
Diagnostic Performance of a Multiplex Circulating Tumor DNA Assay for Lung Cancer Detection
Lung cancer remains the leading cause of cancer-related death worldwide, largely due to late-stage diagnosis. Although low-dose computed tomography (LDCT) screening can reduce mortality, it is limited by high false-positive rates, radiation exposure, a…
-
Utilization of Next-Generation Sequencing (NGS) in Unexplained Cytopenia: Development and Validation of a Predictive Model to Guide Selective Use of Myeloid NGS
Next-generation sequencing (NGS) has improved diagnostic accuracy for myeloid neoplasms, but its clinical utility in assessing unexplained cytopenias remains uncertain. This study aimed to develop an evidence-based tool to guide the optimal and cost-ef…
-
Utilization of Next-Generation Sequencing (NGS) in Unexplained Cytopenia
Next-generation sequencing (NGS) has improved diagnostic accuracy for myeloid neoplasms, but its clinical utility in assessing unexplained cytopenias remains uncertain. This study aimed to develop an evidence-based tool to guide the optimal and cost-ef…
-
AI-guided screening identifies nine drugs that may slow childhood dementia
An Australian research collaboration has identified several existing TGA-approved medicines that could help slow brain damage in children with a rare form of dementia—offering hope for faster treatment options.